Dorothea Wenzel to Lead Surface Solutions Business of Merck KGaA, Darmstadt, Germany
- Benjamin Hein will become Head of Strategy & Transformation in Performance Materials
- Stefan Kratzer appointed new Head of Controlling for the business sector
- Friedhelm Felten will leave the company
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced changes within the leadership team of its Performance Materials business sector. Effective January 1, 2019, Dorothea Wenzel will lead the Surface Solutions business unit within Performance Materials. Benjamin Hein will succeed her as Head of Strategy & Transformation within Performance Materials; Stefan Kratzer will become Head of Controlling.
Dorothea Wenzel joined Performance Materials in April 2018, having transferred from the Healthcare business sector of Merck KGaA, Darmstadt, Germany. She currently is leading Controlling and Strategy & Transformation within Performance Materials. She is currently Head of Controlling, Strategy & Transformation within Performance Materials. Previously, she served as the Head of the Fertility franchise within the Healthcare business sector and as Head of Controlling of the former biopharmaceuticals division of Merck KGaA, Darmstadt, Germany. Dorothea Wenzel succeeds Friedhelm Felten who has decided to pursue new career opportunities outside of Merck KGaA, Darmstadt, Germany.
“I’m happy that Dorothea Wenzel will take over this business-critical role within Performance Materials,” Kai Beckmann, CEO Performance Materials and member of the Executive Board, underscored. “Within only half a year, she was instrumental in creating the new, convincing Performance Materials strategy. In addition, she built a strong structure for the Controlling function and laid the foundation for our five-year transformation by establishing the Bright Future program. Dorothea Wenzel already successfully led the Fertility franchise of Merck KGaA, Darmstadt, Germany, to growth. I expect that she will apply this experience now to Surface Solutions. At the same time, I would like to thank Friedhelm Felten for his strong contributions during his long and successful tenure with Merck KGaA, Darmstadt, Germany. I wish him every success, both professionally and personally.”
Also effective January 1, 2019, Benjamin Hein will take over Dorothea Wenzel’s current role as Head of Strategy & Transformation within Performance Materials, and Stefan Kratzer will become Head of Controlling. Benjamin Hein is currently Head of Group Strategy and the CEO Office at Merck KGaA, Darmstadt, Germany and Stefan Kratzer is Head of Controlling for the Consumer Health business, which is being acquired by Procter & Gamble. Dorothea Wenzel and Benjamin Hein will report to Kai Beckmann, Stefan Kratzer will report to Marcus Kuhnert, Member of the Executive Board and Chief Financial Officer of Merck KGaA, Darmstadt, Germany.
“I’m very happy to have successors for Dorothea Wenzel: Benjamin Hein will contribute the Group perspective very strongly. This is an excellent opportunity for him to support the implementation of the strategy that he already helped to develop in his current position,” said Kai Beckmann.
“We are pleased to have Stefan Kratzer taking over this position, a finance executive within Merck KGaA, Darmstadt, Germany with more than 15 years of international and intercultural experience in Controlling and Finance management positions as well as strong business acumen,” said Marcus Kuhnert. “He has a proven track record in successfully leading some of our finance organizations through major reorganizations and driving teams to high performance.”
Performance Materials comprises the specialty chemicals business of Merck KGaA, Darmstadt, Germany, and supplies solutions for displays, computer chips and surfaces of every kind. The business sector plays a leading role in the electronics market, and also operates in the attractive automotive and cosmetics markets.
Dorothea Wenzel has been working for Merck KGaA, Darmstadt, Germany, since 2004 and is currently responsible for Controlling, Strategy & Transformation in Performance Materials. Previously, she served as the Head of the Fertility franchise within the Healthcare business sector of Merck KGaA, Darmstadt, Germany and as Head of Controlling of the former biopharmaceuticals division of Merck KGaA, Darmstadt, Germany. Before joining Merck KGaA, Darmstadt, Germany, Dorothea Wenzel held various leadership positions on the Rürup Commission of the German Federal Ministry of Health, at the insurance firm Winterthur Versicherung, and at McKinsey. She studied Business and Computer Sciences and earned a doctorate in Health Economics at the Technical University of Darmstadt and at Harvard University.
Benjamin Hein first joined Merck KGaA, Darmstadt, Germany, in 2011 and is currently responsible for Group Strategy and the Group CEO Office. Previously, he was member of Inhouse Consulting and served as the Head of the CEO Office. Before joining Merck KGaA, Darmstadt, Germany, he was employed by Döhler and HAHN Automation. Benjamin Hein studied Business Administration and holds a Master of Science in International Business from Maastricht University (the Netherlands) and a Master of Business from Queensland University of Technology (Australia).
Stefan Kratzer began his professional career at Axaron Biosience AG, a biotech affiliate of BASF. From there, he joined Merck KGaA, Darmstadt, Germany, in 2004 as a Licensing & Business Development Controller. After serving as CFO for the generics business of Merck KGaA, Darmstadt, Germany, in the United States and working in Divisional Controlling at the headquarters of the former biopharmaceuticals division of Merck KGaA, Darmstadt, Germany, in Geneva, he became CFO for the United Kingdom and Ireland and a Regional CFO in Europe with financial responsibilities across all business sectors of Merck KGaA, Darmstadt, Germany, and multiple countries. For the past 18 months Stefan Kratzer has been a member of the Executive Committee of the Consumer Health business of Merck KGaA, Darmstadt, Germany. He holds a Master of Business Administration from the European Business School, Germany, and University of Pittsburgh, USA.
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register for your online subscription of this service as our geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, the vibrant science and technology company, operates across healthcare, life science and performance materials. Around 53,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2017, Merck KGaA, Darmstadt, Germany, generated sales of € 15.3 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck, KGaA, Darmstadt, Germany, visit www.emdgroup.com.
Merck KGaA, Darmstadt, Germany, today provided an overview of its innovative pipeline with a focus on five mid- to late-stage assets with first-in-class and/or best-in-class potential at its R&D Update Call.